Why Oncology Pharmacists Are Central to Sustainable MRD Testing Reimbursement
Minimal residual disease (MRD) testing brings unprecedented sensitivity to detecting microscopic cancer burden, guiding treatment intensification, de-escalation, and surveillance in ways that were unthinkable a decade ago. But as MRD becomes embedded in oncology decision-making, a less visible reality is emerging: MRD’s success isn’t determined solely by clinical utility. It hinges just as much on whether the healthcare system can operationalize and effectively reimburse it.
This is where the pharmacist’s role in a patient’s cancer care team is quietly expanding—not just as a clinical interpreter of MRD results, but as a critical steward of access, documentation, and ultimately, reimbursement.
MRD Testing as a Clinical Compass and Reimbursement Stress Test
A recent article in Pharmacy Times frames MRD as a “therapeutic compass,” enabling adaptive oncology strategies based on measurable disease biology rather than symptoms alone. Oncology pharmacists are increasingly responsible for interpreting MRD kinetics, aligning therapy adjustments, and managing toxicity risks across the treatment continuum.
Yet MRD is not a single event; it is longitudinal by design. Multiple tests across induction, consolidation, and surveillance phases create a cascade of operational and financial touchpoints. XiFin’s analysis of MRD testing, billing, and reimbursement underscores this reality: MRD testing requires repeated assessments, complex molecular interpretation, and ongoing monitoring, all of which introduce billing and reimbursement complexity at each step.
In other words, MRD doesn’t just test patients—it tests the system.
Why MRD Reimbursement Remains Inconsistent
Despite a strong clinical rationale, MRD reimbursement remains inconsistent and fragmented. Payor policies vary widely across:
- Testing methodologies (e.g., NGS vs. flow cytometry)
- Clinical indications (relapse detection vs. remission monitoring)
- Frequency limits and timing requirements
- Documentation and prior authorization criteria
This variability creates a paradox: a test that informs life-altering treatment decisions is often denied for lack of “medical necessity,” insufficient documentation, or classification as investigational. In fact, XiFin data shows that nearly one-third of MRD denials are tied directly to medical necessity determinations.
For pharmacists, this introduces a new dimension of responsibility. The interpretation of MRD results is no longer enough—the clinical narrative surrounding those results must be translated into documentation that aligns with evolving payor expectations.
How Pharmacists Connect Clinical Decisions to Payor Policy
The Pharmacy Times article highlights pharmacists as “bridges between laboratory findings and clinical applications.” Increasingly, they must also bridge clinical intent and reimbursement logic.
Consider the key friction points:
- Documenting Medical Necessity for MRD Testing
MRD’s value is often tied to longitudinal trends rather than a single diagnostic result. Pharmacists are uniquely positioned to contextualize these trends, linking MRD diagnostic data to therapy decisions, relapse risk, and treatment duration. This narrative is precisely what payors require but often fail to see. - Alignment with Coverage Criteria
Payors may differentiate between MRD use cases (e.g., post-treatment surveillance vs. initial risk stratification). Pharmacists, embedded in care teams, can help ensure that test ordering aligns with covered indications and that clinical intent is clearly documented. - Anticipating Prior Authorization Requirements
XiFin data indicates that prior authorization is a major operational bottleneck, driven by fragmented policies, manual interpretation, and inconsistent documentation. Pharmacists can anticipate these requirements earlier in the care pathway, helping assemble the clinical evidence needed for approval before delays occur.
Understanding the Coding and Billing Complexity of MRD Testing
The complexity of MRD reimbursement extends beyond documentation into coding and claims management strategy. For example, diagnostic providers must navigate:
- Unlisted CPT pathways (e.g., 81479) vs. PLA codes
- The Diagnostic Exchange (DEX) Z-Code™ requirements under the MolDX® Program and expanding commercial adoption
- Bundled vs. fee-for-service reimbursement structures
These are not traditionally clinical concerns, but their downstream impact is clinical. Delayed reimbursement can delay testing. Denials can limit access. Administrative friction can discourage adoption altogether.
Pharmacists, particularly in oncology, are increasingly participating in multidisciplinary workflows that intersect with these decisions. Understanding how MRD is coded, billed, and adjudicated is becoming part of ensuring that patients can receive the care their individual biology demands.
Preventing MRD Denials Before Claims Are Submitted
One of the most striking insights from XiFin’s data is how difficult it is to recover revenue once MRD claims are denied. XiFin customers find that first-level appeal success rates can be as low as 6% among major commercial payors. This shifts the emphasis upstream, from recovery to prevention.
The traditional boundary between clinical decision-making and administrative execution is dissolving.
For pharmacists, this reinforces the importance of:
- Ensuring complete and accurate clinical documentation at the point of order
- Coordinating with diagnostic provider and revenue cycle teams on test selection and timing
- Anticipating policy misalignment before submission
Aligning Clinical, Revenue Cycle Management, and Market Access Teams
MRD is inherently multidisciplinary; therefore, its reimbursement must be as well. Effective alignment is needed across:
- Clinical teams, including pharmacists
- Revenue cycle management
- Market access and payor strategy
When these functions operate in silos, the consequences are predictable: denials, delays, and inconsistent patient access, all of which can postpone or even prevent vital patient care. When aligned, they create a feedback loop in which clinical insight informs policy strategy and reimbursement data informs clinical workflows.
Pharmacists sit at the center of this intersection, uniquely positioned to translate across domains.
Four Emerging Roles for Oncology Pharmacists in MRD Testing
The evolution of MRD demands a reframing of oncology pharmacy practice. It is no longer sufficient to manage drugs and monitor toxicity. Pharmacists are becoming more critical in the roles of:
- Data interpreter, translating MRD signals into actionable therapy decisions
- Documentation architect, shaping the clinical narrative that supports reimbursement
- Workflow integrator, aligning testing, treatment, and authorization processes
- Access advocate, ensuring that innovation reaches patients without administrative erosion
In this sense, pharmacists are not just at the helm of adaptive oncology; they are increasingly at the helm of its sustainability.
Sustaining the Path from Detection to Impact
MRD testing represents the promise of precision medicine: treating the disease we can measure, not just the disease we can see. As MRD adoption accelerates, the limiting factor will not be detection sensitivity—it will be alignment of clinical, operational, and financial systems.
Pharmacists, long valued for their role in optimizing therapy, are emerging as critical agents in aligning these systems. Their expanding influence reflects a broader truth: in modern oncology, the pathway from innovation to impact runs through reimbursement.
Learn more about Navigating the Clinical and Financial Complexities of MRD Testing.